Cytoplasmic β-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: Potential implications for melanoma tumorigenesis?

British Journal of Dermatology

Volumn 160, Issue 3, 2009, Pages 600-608

  De Panfilis, G ^a   Ferrari, D ^a   Santoro, S ^a   Ricci, R ^b   Lombardi, M ^a   Pedrazzi, G ^b   Pepe, C ^a   Cortelazzi, C ^a   Santini, M ^a  

^a UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

catenin; Melanoma associated naevi; Naevus associated melanomas; Tumorigenesis

Indexed keywords

BETA CATENIN;

ADULT; AGED; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ELECTRIC POTENTIAL; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; MUTATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEVUS, PIGMENTED; SKIN NEOPLASMS; YOUNG ADULT;

EID: 60449087963     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.09001.x     Document Type: Article

References (72)

1. Ozawa M, Baribault H, Klemer R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989 8 : 1711 17.
2. McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science 1991 254 : 1359 61.
3. Morin PJ. Beta-catenin signaling and cancer. BioEssays 1999 21 : 1021 30.
4. Larue L, Kumasaka M, Goding CR. Beta-catenin in the melanocytic lineage. Pigment Cell Res 2003 16 : 312 17.
5. Pećina-Šlaus N, Žigmund M, Kušec V et al. E-cadherin and β-catenin expression patterns in malignant melanoma assessed by image analysis. J Cutan Pathol 2007 34 : 239 46.
6. Sanders DSA, Blessing K, Hassan GAR et al. Alterations in cadherin and catenin expression during biological progression of melanocytic tumours. Mol Pathol 1999 52 : 151 7.
7. Kageshita T, Hamby CV, Ishihara T et al. Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001 145 : 210 16.
8. Maelandsmo GM, Holm R, Nesland JM et al. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003 9 : 3383 8.
9. Krengel S, Grotelüschen F, Bartsch S, Tronnier M. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. J Cutan Pathol 2004 31 : 1 7.
10. Kreizenbeck GM, Berger AJ, Subtil A et al. Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2008 17 : 949 58.
11. Tucci MG, Lucarini G, Brancorsini D et al. Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 2007 157 : 1212 16.
12. Johnson JP, Stade BG, Holzmann B et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 1989 86 : 641 4.
13. Natali P, Nicotra MR, Cavaliere R et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990 50 : 1271 8.
14. Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 1992 167 : 187 91.
15. Sanders DS, Evans AT, Allen CA et al. Classification of CEA related positivity in primary and metastatic malignant melanoma. J Pathol 1994 172 : 343 8.
16. Nesbit M, Herlyn M. Adhesion receptor in human melanoma progression. Invasion Metastasis 1994 14 : 131 46.
17. Boccaletti V, Temponi M, Wang Z et al. The vitronectin receptor alpha-v beta-3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines. Acta Derm Venereol (Stockh) 1996 76 : 269 73.
18. Friedman RJ, Rigel DS, Kopf AW et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic naevi. Arch Dermatol 1983 119 : 455 62.
19. Urso C, Giannotti V, Reali UM et al. Spatial association of melanocytic naevus and melanoma. Melanoma Res 1991 1 : 245 9.
20. Harley S, Walsh N. A new look at naevus associated melanomas. Am J Dermatopathol 1996 18 : 137 41.
21. Massi D, Carli P, Franchi A, Santucci M. Naevus-associated melanomas: cause or chance? Melanoma Res 1999 9 : 85 91.
22. Smolle J, Kaddu S, Kerl H. Non-random spatial association of melanoma and naevi - a morphometric analysis. Melanoma Res 1999 9 : 407 12.
23. Kaddu S, Smolle J, Zenahlik P et al. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 2002 12 : 271 8.
24. Clark WH Jr., Elder DE, Guerry D IV. et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984 12 : 1147 65.
25. Herlyn M, Clark WH, Rodeck U et al. Biology of tumour progression in human melanocytes. Lab Invest 1987 56 : 461 74.
26. Streijlen PM, Hamm H, van Erp EJ et al. Immunohistologic evidence for the malignant potential of congenital melanocytic naevi. J Invest Dermatol 1989 92 : 366 70.
27. Mark GJ, Mihm MC, Liteplo MG et al. Congenital melanocytic nevi of the small and garment type: clinical, histologic and ultrastructural studies. Hum Pathol 1973 4 : 395 418.
28. Stenn KS, Arons M, Hurwitz S. Patterns of congenital nevocellular nevi. A histologic study of thirty-eight cases. J Am Acad Dermatol 1983 9 : 388 93.
29. Rhodes AR, Silverman RA, Harrist TJ, Melski EV. A histologic comparison of congenital and acquired nevomelanocytic nevi. Arch Dermatol 1985 121 : 1266 73.
30. Ackerman AB, Cerroni L, Kerl H. Pitfalls in Histopathologic Diagnosis of Malignant Melanoma. Philadelphia, PA : Lea & Febiger, 1994.
31. Balch CM, Soong SJ, Atkins MB et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004 54 : 131 4.
32. De Panfilis G, Campanini M, Santini M et al. Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol 2008 128 : 676 84.
33. Ferrari D, Lombardi M, Ricci R et al. Dermatopathological indicators of melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma. J Cutan Pathol 2007 34 : 705 12.
34. Rubinfeld B, Robbins P, El-Gamil M et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997 275 : 1790 2.
35. Rimm DL, Casa K, Hu G et al. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999 154 : 325 9.
36. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous melanoma. Int J Cancer 2001 92 : 839 42.
37. Nagafuchi A, Takeichi M. Cell binding function of E-cadherin is regulated by the cytoplasmic domain. EMBO J 1988 7 : 3679 84.
38. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 1995 72 : 506 12.
39. Shimazui T, Schalken JA, Giroldi LA et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumours. Cancer Res 1996 56 : 4154 8.
40. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signalling in colon cancer by mutations in beta-catenin or APC. Science 1997 398 : 1787 90.
41. Novellino L, De Filippo A, Deho P et al. PTPRK negatively regulates trancriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. Cell Signal 2008 20 : 872 83.
42. Grabacka M, Placha W, Urbanska K et al. PPAR gamma regulates MITF and β-catenin expression and promotes a differentiated phenotype in mouse melanoma S91. Pigment Cell Melanoma Res 2008 21 : 388 96.
43. Behrens J, von Kries JP, Kuhl M et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996 382 : 638 42.
44. Molenaar M, van de Wetering M, Oosterwegel M et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996 86 : 391 9.
45. Huber O, Korn R, McLaughlin J et al. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 1996 59 : 3 10.
46. Larue L, Delmas V. The Wnt/beta-catenin pathway in melanoma. Front Biosci 2006 11 : 733 42.
47. Barker N, Morin PJ, Clevers H. The yin-yang of Tcf/beta-catenin signaling. Adv Cancer Res 2000 77 : 1 24.
48. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000 103 : 311 20.
49. Seidensticker MJ, Behrens J. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 2000 1495 : 168 82.
50. Munemitsu S, Albert I, Souza B et al. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumour suppressor protein. Proc Natl Acad Sci USA 1995 92 : 3046 50.
51. Jankowski JA, Bruton R, Shepherd N, Sanders DS. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. Mol Pathol 1997 50 : 289 90.
52. Balint K, Xiao M, Pinnix CC et al. Activation of Notch 1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 2005 115 : 3166 76.
53. Reifenberger J, Knobbe CB, Wolter M et al. Molecular genetic analysis of malignant melanomas for aberrations of WNT signaling pathway genes CTNNB1, APC, ICAT, and BTRC. Int J Cancer 2002 100 : 549 56.
54. Elder DE, Greene MH, Bomdi EE, Clark WH Jr. Acquired melanocytic naevi and melanoma. The dysplastic nevus syndrome. In : Pathology of Malignant Melanoma (Ackerman AB, ed New York : Masson, 1981 185 215.
55. Black WC. Residual dysplastic and other naevi in superficial spreading melanoma. Clinical correlations and association with sun damage. Cancer 1988 62 : 163 73.
56. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer 1989 63 : 550 5.
57. Tannous ZS, Mihm MC Jr., Sober AJ, Duncan LM. Congenital melanocytic naevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005 52 : 197 203.
58. Ka VS, Dusza SW, Halpern AC, Marghoob AA. The association between large congenital melanocytic naevi and cutaneous melanoma: preliminary findings from an Internet-based registry of 379 patients. Melanoma Res 2005 15 : 61 7.
59. Bachmann IM, Straume O, Putervoll HE, Akslen LA. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005 11 : 8606 14.
60. Demirkan NC, Kesen Z, Akdag B et al. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions. Clin Exp Dermatol 2007 32 : 733 9.
61. Daniotti M, Oggionni M, Ranzani T et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004 23 : 5968 77.
62. Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998 110 : 932 8.
63. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003 22 : 3063 9.
64. van Schanke A, van Venrooij GM, Jongsma MJ et al. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. Cancer Res 2006 66 : 2608 15.
65. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002 417 : 949 54.
66. Pollock PM, Trent JM. The genetics of cutaneous melanoma. Clin Lab Med 2000 20 : 667 90.
67. INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007 21 : 2923 35.
68. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005 125 : 1242 51.
69. Liu X, Driskell RR, Luo M et al. Characterization of Lef-1 promoter segments that facilitate inductive developmental expression in skin. J Invest Dermatol 2004 123 : 264 74.
70. Widelitz RB, Jiang TX, Lu J. Beta-catenin in epithelial morphogenesis: conversion of part of avian foot scales into feather buds with a mutated beta-catenin. Dev Biol 2000 219 : 98 114.
71. Widlund HR, Horstman MA, Price ER et al. Beta-catenin-induced melanoma growth requires the downstream target microphthalmia-associated transcription factor. J Cell Biol 2002 158 : 1079 87.
72. Conacci-Sorell ME, Ben-Yedidia T, Shutman M et al. Nr-Cam is target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances mobility and confers tumorigenesis. Genes Dev 2002 16 : 2058 72.